Canada's Crescita Q1 revenue rises on manufacturing growth

Crescita Therapeutics

11/05/2026 12:38

Overview

Canada dermatology firm's Q1 revenue rose year-over-year, driven by manufacturing and skincare sales

Adjusted EBITDA turned positive in Q1, reflecting improved operating performance

Company progressing with proposed acquisition by ClinActiv, with closing expected in Q2 2026

Outlook

Company expects ClinActiv acquisition to close in Q2-2026, pending shareholder and court approval

Result Drivers

MANUFACTURING VOLUMES - Higher production volumes in the Manufacturing segment, including fulfillment of large orders, drove revenue growth

SKINCARE SALES - Incremental revenue from acquired Bacti Control, higher e-commerce sales, and increased exports to Asian markets boosted Skincare segment

GROSS MARGIN - Gross margin improved due to increased manufacturing volumes, partly offset by a higher proportion of lower-margin Manufacturing revenue

Company press release: ID:nBwbW0F9Qa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
C$5.64 mln
Q1 Adjusted EBITDA
C$238,000
Q1 Gross Margin
46.90%
Q1 Operating Expenses
C$3.85 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)